[Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant 
Gene Mutation in Advanced Lung Adenocarcinoma].

ABSTRACT:

Background

Osimertinib is approved by Food and Drug Administration for patients with advanced non-small cell lung cancer carrying EGFR-T790M mutations. Osimertinib therapy was missed in many patients who were unable to perform biopsy due to occult lesion progression or weak body. In this study. We hope that some proteins associated with predicting EGFR-T790M resistance could be screened from the serum to provide help for clinical medication. The aim of this study is to explore the protein associated with EGFR-T790M drug resistance gene and provide help for clinical medication.

Methods

In this study, 36 patients with advanced lung adenocarcinoma treated by gefitinib were included. After the disease progression of the patients, biopsy was performed. 18 patients in the EGFR-T79

SUBMITTER: Chen L 

PROVIDER: S-EPMC7679218 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature